Synergistic approaches to clinical oncology biomarker discovery

Current Topics in Medicinal Chemistry

Volumn 5, Issue 11, 2005, Pages 1047-1051

  Belkowski, Stanley M ^a   Polkovitch, Deborah ^a   D'Andrea, Michael R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Biomarker; Functional informatics; Genomics; Histology; Integration; Oncology; Proteomics

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAMPTOTHECIN; COMPLEMENTARY DNA; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GEFITINIB; RHO FACTOR; SMALL INTERFERING RNA;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER; CEREBROSPINAL FLUID; CLINICAL TRIAL; COLON CANCER; COST BENEFIT ANALYSIS; DNA MICROARRAY; GENE EXPRESSION; GENE TARGETING; GENOMICS; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; METASTASIS; ONCOLOGY; OVARY CANCER; PHARMACOGENOMICS; PROTEIN INTERACTION; PROTEOMICS; REVIEW; SIDE EFFECT; TOXICITY TESTING; VALIDATION PROCESS;

DRUG EVALUATION, PRECLINICAL; GENOMICS; HISTOCYTOCHEMISTRY; HUMANS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 27744514484     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802605774297074     Document Type: Review

References (39)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
2. Ilyin, S. E.; Pinhasov, A.; Vaidya, A. H.; Amato, F. A.; Kauffman et al. Emerging paradigms in applied bioinformatics. BioSilico. 2003, 3: 86-88.
3. Bast, R. C. Jr.; Urban, N.; Shridhar, V.; Smith, D.; Zhang, Z. et al. Early detection of ovarian cancer: promise and reality. Cancer Treat. Res. 2002, 107, 61-97.
4. Pinhasov, A.; Mei, J.; Amaratunga, D.; Amato, F. A.; Lu, H. et al. Gene expression analysis for high throughput screening applications. Comb. Chem. High Throughput Screen 2004, 7, 133-140.
5. Stevens, E. V.; Liotta, L. A.; Kohn, E. C. Proteomic analysis for early detection of ovarian cancer: a realistic approach? Int. J. Gynecol. Cancer 2003, 13, 133-139.
6. Bast, R. C. Jr.; Xu, F. J.; Yu, Y. H.; Barnhill, S.; Zhang, Z. et al. CA 125: the past and the future. Int. J. Biol. Markers 1998, 13, 179-187.
7. Rai, A. J.; Zhang, Z.; Rosenzweig, J.; Shih Ie, M.; Pharn, T. et al. Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 2002, 126, 1518-1526.
8. Mok, S. C.; Chao, J.; Skates, S.; Wong, K.; Yin, G. K. et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl. Cancer Inst. 2001, 93, 1458-1464.
9. Li, J.; Zhang, Z.; Rosenzweig, J.; Wang, Y. Y.; Chan, D. W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 2002, 48, 1296-1304.
10. Vlahou, A.; Schellhammer, P. F.; Mendrinos, S.; Patel, K.; Kondylis, F. I. et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001, 158, 1491-1502.
11. Sedlaczek, P.; Frydecka, I.; Gabrys, M.; Van Dalen, A.; Einarsson, R. et al. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 2002, 95, 1886-1893.
12. Griffin, T. J.; Gygi, S. P.; Ideker, T.; Rist, B.; Eng, J. et al. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol. Cell. Proteomics 2002, 1, 323-333.
13. Aardema, M. J.; MacGregor, J. T. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat. Res. 2002, 499, 13-25.
14. Nebert, D. W.; Vesell, E. S. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur. J. Pharmacol. 2004, 500, 267-280.
15. Tamura, K.; Fukuoka, M. Gefitinib in non-small cell lung cancer. Expert Opm. Pharmacother. 2005, 6, 985-993.
16. Pennie, W. D. Use of cDNA microarrays to probe and understand the toxicological consequences of altered gene expression. Toxicol. Lett. 2000, 112-113, 473-477.
17. Mattison, L. K.; Soong, R.; Diasio, R. B. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002, 3, 485-492.
18. Mauri, P.; Scarpa, A.; Nascimbeni, A. C.; Benazzi, L.; Parmagnani, E. et al. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J. 2005, 19, 1125-1127. Epub 2005 May 1124.
19. Yu, J. K.; Chen, Y. D.; Zheng, S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol. 2004, 10, 3127-3131.
20. Malik, G.; Ward, M. D.; Gupta, S. K.; Trosset, M. W.; Grizzle, W. E. et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 2005, 11, 1073-1085.
21. Cho, W. C.; Yip, T. T.; Yip, C.; Yip, V.; Thulasiraman, V. et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 2004, 10, 43-52.
22. Berman, D. M.; Shih Ie, M.; Burke, L. A.; Veenstra, T. D.; Zhao, Y. et al. Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). Proteomics 2004, 4, 812-818.
23. Schena, M.; Shalon, D.; Heller, R.; Chai, A.; Brown, P. O. et al. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc. Natl. Acad. Sci. USA 1996, 93, 10614-10619.
24. Beltrami, A. C.; Puglisi, F.; Di Lauro, V.; Scalone, S.; Amoroso, V. et al. Biomarkers and histology of premalignant and malignant lesions. Eur. J. Cancer Prev. 1996, 5, 375-376.
25. Junker, K.; Hindermann, W.; von Eggeling, F.; Diegmann, J.; Haessler, K. et al. CD70: a new tumor specific biomarker for renal cell carcinoma. J. Urol. 2005, 173, 2150-2153.
26. Gupta, D.; Bronstein, I. B.; Holden, J. A. Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. Hum. Pathol. 2000, 31, 214-219.
27. D'Andrea, M. R., Farber, P., Foglesong, P. D. Immunohistochemical detection of DNA topoisomerase IIa and IIb compared with detection of Ki-67, a marker of cellular proliferation, in human tumors. Appl. Immunohisto. 1994, 2, 177-185.
28. Kyrgidis, A.; Kountouras, J.; Zavos, C.; Chatzopoulos, D. New molecular concepts of Barrett's esophagus: clinical implications and biomarkers. J. Surg. Res. 2005, 125, 189-212.
29. Chen, G.; Gharib, T. G.; Huang, C. C.; Taylor, J. M.; Misek, D. E. et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell Proteomics 2002, 1, 304-313.
30. Hanash, S. M.; Bobek, M. P.; Rickman, D. S.; Williams, T.; Rouillard, J. M. et al. Integrating cancer genomics and proteomics in the post-genome era. Proteomics 2002, 2, 69-75.
31. Orntoft, T. F.; Thykjaer, T.; Waldman, F. M.; Wolf, H.; Celis, J. E. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol. Cell. Proteomics 2002, 1, 37-45.
32. Nishizuka, S.; Chen, S. T.; Gwadry, F. G.; Alexander, J.; Major, S. M. et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 2003, 63, 5243-5250.
33. Huber, M.; Bahr, I.; Kratzschmar, J. R.; Becker, A.; Muller, E. C. et al. Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol. Cell. Proteomics 2003, 13, 13.
34. Gygi, S. P.; Rochon, Y.; Franza, B. R.; Aebersold, R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 1999, 19, 1720-1730.
35. Belkowski, S. M.; Colburn, R. W.; Stone, D. J.; Van Besien, C. R.; Polkovitch, D. et al. The discovery of stannin in rat dorsal root ganglia using an integrated proteohistological approach: Potential role in inflammatory hyperalgesia. Clinical Proteomics 2004, 1(3-4), 249-258.
36. Armstrong, G.; Szallasi, A.; Biegel, J. A.; Shurtleff, S.; Bilaniuk, L. T. et al. Early molecular detection of central nervous system relapse in a child with systemic anaplastic large cell lymphoma: case report and review of the literature. Pediatr. Blood Cancer 2005, 44, 400-406.
37. Bernal, A.; J. Kauffman; H. Xin; F.A. Amato; C. Chen et al. Emerging opportunities in functional informatics. PharmaGenomics 2003.
38. Belkowski, S.; Ilyin, S. E. Integrative functional informatics. Drug Disc. Develop. 2003, 10, 77-78.
39. Ilyin, S. E.; Belkowski, S. M.; Plata-Salaman, C. R. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 2004, 22, 411-416.